ストックスクリーナーアプリを入手
0.6768
3.33%
0.0218
アフターアワーズ：
.68
0.0032
+0.47%
前日終値:
$0.655
開ける：
$0.631
24時間の取引高:
26,252
Relative Volume:
0.05
時価総額：
$2.93M
収益：
$7,500
当期純損益:
$-9.84M
株価収益率:
-0.1182
EPS:
-5.7263
ネットキャッシュフロー:
$-9.25M
1週間 パフォーマンス:
+12.99%
1か月 パフォーマンス:
-23.61%
6か月 パフォーマンス:
-50.24%
1年 パフォーマンス:
-87.89%
1日の値動き範囲:
$0.631
$0.6793
1週間の範囲:
$0.5701
$0.6899
52週間の値動き範囲:
$0.5038
$9.60
Oragenics Inc Stock (OGEN) Company Profile
名前
Oragenics Inc
セクター
電話
813-286-7900
住所
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.6768 | 2.84M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oragenics Inc (OGEN) 最新ニュース
Earnings Recap: Is Oragenics Inc gaining market shareWeekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Oragenics Doses First Patient in Phase IIa Trial for Potential Concussion Treatment - citybuzz -
Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia - TipRanks
Oragenics Doses First Patient in Phase IIa Trial of ONP-002 for Concussion, Targeting Unmet Need in Mild Traumatic Brain Injury 1 - Minichart
Oragenics doses first patient in Phase IIa trial of ONP-002 for concussion - TradingView — Track All Markets
With no approved concussion drug, Oragenics starts patient dosing - Stock Titan
Sectors Review: Is Oragenics Inc stock technically oversold2026 Institutional & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Oragenics (OGEN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Nasdaq Moves: Is Oragenics Inc vulnerable to short sellersQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Risk On: Is Oragenics Inc gaining market sharePrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Rally Mode: Is Oragenics Inc gaining market share2026 Trading Volume Trends & Long-Term Capital Growth Strategies - baoquankhu1.vn
0A64.IL,0P0001LL1F,111 (0A64.IL) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Oragenics Inc (UAV.BE) Stock Price, News, Quote & History - ca.finance.yahoo.com
OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics Sets New 2025 Annual Shareholder Meeting Date - The Globe and Mail
Oragenics: CEO Highlights "Undervalued" Pipeline Amid Significant Insider Sale of 35% Ownership - Bitget
Oragenics (OGEN) schedules 2025 shareholder meeting and sets May 1, 2026 proposal cutoff - Stock Titan
Risks Report: What is the target price for Oragenics Inc stockDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations - citybuzz -
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - Sahm
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Oragenics, Inc.: Fundamental Analysis and Financial Ratings | UAV0 | US6840236094 - marketscreener.com
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - Sahm
Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment - citybuzz -
Oragenics Inc Initiates Phase Iia Clinical Trial Site Activation - marketscreener.com
Oragenics (OGEN) Advances Phase IIa Clinical Trial of ONP-002 in Australia - GuruFocus
Oragenics begins testing nasal concussion treatment in Australia - Stock Titan
Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury - Minichart
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions - TipRanks
Oragenics Explores CNS Asset Acquisitions to Expand Brain Health Pipeline - citybuzz -
Oragenics (OGEN) Eyes Expansion in Central Nervous System Sector - GuruFocus
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - The Manila Times
Oragenics Explores Expansion of CNS Platform - Moomoo
Oragenics (OGEN) Receives Approval for Phase IIa Concussion Drug Trial in Australia - GuruFocus
Oragenics Receives HREC Approval for Phase IIa Clinical - GlobeNewswire
Is Oragenics Inc forming bullish engulfing patterns2025 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Inflation Data: Is Oragenics Inc a strong candidate for buy and holdJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Aug Technicals: What is the target price for Oragenics Inc stockPortfolio Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
Oragenics Inc (OGEN) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):